Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATH-1105 a Phase 1, Double-Blind, Placebo-Controlled, Single-and-Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Male and Female Subjects

Next Previous
Trial Profile

ATH-1105 a Phase 1, Double-Blind, Placebo-Controlled, Single-and-Multiple-Oral-Dose, Safety, Tolerability, and Pharmacokinetic Study in Healthy Male and Female Subjects

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 03 Dec 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATH 1105 (Primary)
  • Indications Amyotrophic lateral sclerosis; Frontotemporal dementia
  • Focus Adverse reactions; First in man
  • Sponsors Athira Pharma

Most Recent Events

  • 06 Nov 2025 According to an Athira Pharma media release, the company presented data from phase 1 clinical trial of ATH-1105 at the 4th Annual ALS Drug Development Summit.
  • 14 Aug 2025 According to an Athira Pharma media release, the company presented results from this phase 1 clinical trial of ATH-1105 in healthy volunteers at the ALS Nexus 2025 conference in Dallas, Texas.
  • 13 May 2025 Results presented in the Athira Pharma Media Release.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top